# D07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced Biliary Tract Cancer

Source: https://onco.cc/trials/nct06622057/  
OnCo record `nct06622057` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing D07001 in biliary tract cancer, now recruiting.

## Summary

D07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced Biliary Tract Cancer is a phase 3 interventional study registered as NCT06622057, led by InnoPharmax, and recruiting on the registry. Official title: Phase III, Randomised, Double-blind Study of Combination Therapy With D07001-Softgel Capsules and Capecitabine vs Placebo and Capecitabine in Patients With Advanced BTC After Failed on Gemcitabine, Platin, and FOLFOX or Irinotecan Regimens. Planned enrolment is 240 participants (estimated). The study started in 2026-06-09 and primary completion is expected in 2028-12-31. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Tags: ctgov-ingest
- Registry id: NCT06622057
- Phase: 3
- Setting: Phase III, Randomized, Double-blind Study of Combination Therapy With D07001-Softgel Capsules and Capecitabine vs Placebo and Capecitabine in Patients With Advanced BTC After Failed on Gemcitabine, Platin, and FOLFOX or Irinotecan Regimens
- Sponsor: InnoPharmax
- Enrolled: 240

## Sources

- ClinicalTrials.gov NCT06622057: https://clinicaltrials.gov/study/NCT06622057

## Connected records

- cancers: [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/)
- drugs: [D07001](https://onco.cc/drugs/d07001/)
- companies: [InnoPharmax](https://onco.cc/companies/innopharmax/)

---
JSON: https://onco.cc/api/v1/entities/nct06622057.json